Format

Send to

Choose Destination
Int J Pharm. 2014 Apr 25;465(1-2):317-24. doi: 10.1016/j.ijpharm.2014.01.034. Epub 2014 Feb 19.

Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.

Author information

1
Department of Clinical Pharmacy, Meander Medical Center, Amersfoort, The Netherlands. Electronic address: rob@terheine.nl.
2
Department of Clinical Pharmacy, Meander Medical Center, Amersfoort, The Netherlands.
3
Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands.
4
Section Radiation, Detection & Medical Imaging, TU Delft & MILabs B.V., Utrecht, The Netherlands.
5
Department of Clinical Chemistry, Meander Medical Center, Amersfoort, The Netherlands.
6
Department of Radiology & Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands.
7
Department of Clinical Pharmacology & Pharmacy, VU University Medical Center, Amsterdam, The Netherlands.

Abstract

Bone-targeting therapeutic radiopharmaceuticals are effective agents for treatment of painful bone metastases. Rhenium-188-HEDP is such a therapeutic radiopharmaceutical and has advantages over commercially available alternatives in terms of efficacy, safety and the ability to be produced on-site, allowing rapid treatment upon presentation of patients with pain. Unlike many other radiopharmaceuticals, there are no standardized preparation methods for Rhenium-188-HEDP. It is known, however, that drug composition may not only affect stability of the final drug product, but it may also influence bone affinity and, thus, efficacy. Furthermore, for support of clinical studies with Rhenium-188-HEDP as an investigational medicinal product, preparation of this radiopharmaceutical has to be performed under GMP conditions. To our knowledge, no group has reported on the preparation of Rhenium-188-HEDP under GMP conditions or on stock production of sterile non-radioactive starting materials. We present the production of GMP grade Rhenium-188-HEDP for application of this therapeutic radiopharmaceutical in routine clinical practice and for support of clinical studies. In addition, bio-distribution data of Rhenium-188-HEDP in mice and in patients with bone metastases originating from prostate cancer are presented.

KEYWORDS:

Bone metastases; GMP; Prostate cancer; Radionuclide therapy; Rhenium-188; Rhenium-188-HEDP

PMID:
24560635
DOI:
10.1016/j.ijpharm.2014.01.034
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center